Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies.

@article{Viswanatha2021EfficacyAS,
  title={Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies.},
  author={Gollapalle Lakshminarayanashastry Viswanatha and CH.K.V.L.S.N. Anjana Male and Hanumanthappa Shylaja},
  journal={Clinical and experimental rheumatology},
  year={2021},
  pages={
          
        }
}
OBJECTIVES This systematic review and meta-analysis was aimed to evaluate the efficacy and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19). METHODS The electronic search was made using PubMed, Scopus, CENTRAL, and Google scholar to identify the retrospective observational reports. The studies published from 01 January 2020 to 30th October 2020. Participants were hospitalised COVID-19 patients. Interventions included tocilizumab versus placebo/standard of… 
4 Citations

Figures and Tables from this paper

Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review

Tocilizumab treatment reduced therisk of intubation, mortality and the length of hospital stay, without increasing the risk of superimposed infections in COVID‐19 patients.

Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics

Future clinical trials should be designed to standardize clinical approaches, with appropriate organization, patient selection, addition of control groups, and careful identification of disease phase to reduce heterogeneity and bias and should rely on the integration of scientific societies to promote a consensus on interpretation of the data and recommendations for optimal COVID-19 therapies.

Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study

A high SOFA score and a high Charlson score resulted associated with BSI’s development and immunosuppressive therapy like steroids and tocilizumab, has no role in increasing the risk of bacteremia.

The response to COVID 19 across countries and the implications for future pandemics

The objective was to establish an experimental procedure and show direct results that unequivocally can be assigned asbestosis of central nervous system disorders and provide a prognosis for prognosis in patients with central nervous disease.

References

SHOWING 1-10 OF 49 REFERENCES

Efficacy and Safety of Tocilizumab in the Treatment of SARS-CoV-2: A Systematic Review and Meta-analysis

Using tocilizumab treatment for moderate to severe COVID-19 patients caused by SARS-CoV-2, along with caution for superinfections is recommended, with current evidence on efficacy and safety of tocilIZumab.

Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence

Results based on pooled studies show tocilizumab to be safe and efficacious in reducing mortality among critically ill COVID-19 patients, but due to the limited number of observational studies, the positive findings should be viewed cautiously and warrant further investigation.

Efficacy and safety of tocilizumab in COVID-19 patients: A Meta-Analysis

Tocilizumab improves the clinical outcome of COVID-19 patients, especially in severe cases, and the optimal timing of administration may provide the guidance for management, however, tocilIZumab may be used with caution in solid transplant recipients for the suboptimal efficacy.

Efficacy of tocilizumab in COVID‐19: A systematic review and meta‐analysis

The addition of TOC to SOC has the potential to reduce mortality and need for mechanical ventilation in patients with severe COVID‐19 and Randomized controlled trials are needed to validate this.

Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis

The addition of TCZ to the SOC might reduce mortality in severe COVID-19 and more extensive randomized clinical trials are needed to validate these findings.

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

Treatment with TCZ did not reduce ICU admission or mortality rate in a cohort of 21 patients, and analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels.

Efficacy and safety of tocilizumab in COVID-19 patients

Findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19, however, future clinical trials are needed to better understand the impact of tocilIZumab interference with IL-6 and provide a therapeutic strategy for treatment.